PMID-23958540 – Linaclotide Inhibits Colonic Nociceptors via GC-C and cGMP
Castro J, Harrington AM, Hughes PA, et al. "Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate," Gastroenterology, 2013;145(6):1334-1346.e11.
Quick Reference
| Property | Value |
|---|---|
| PMID | 23958540 |
| DOI | 10.1053/j.gastro.2013.08.017 |
| Year | 2013 |
| Journal | Gastroenterology |
| Study Type | Animal in vivo + In vitro |
| Evidence Level | V |
| Sample | Mouse models of visceral hypersensitivity + ex vivo colonic preparations |
| Peptide(s) Studied | Linaclotide |
Key Findings
- Linaclotide activates GC-C on intestinal epithelial cells, producing intracellular cGMP which is then exported to the extracellular space
- Extracellular cGMP directly inhibits colonic nociceptors, reducing their firing in response to mechanical stimulation
- The analgesic effect is independent of the secretory (pro-motility) effect — pain relief occurs via a separate cGMP-mediated pathway
- Linaclotide inhibited colonic nociceptors with greater efficacy during chronic visceral hypersensitivity than in normal conditions
- Intra-colonic administration reduced signaling of noxious colorectal distension to the spinal cord
- This study provided the first mechanistic explanation for why linaclotide relieves abdominal pain in IBS-C patients
Study Design
Combined in vivo mouse model and ex vivo colonic afferent nerve recording studies. Used both wild-type and GC-C knockout mice. Assessed nociceptor firing in response to mechanical and chemical stimuli with and without linaclotide. Measured cGMP levels in lumen, mucosa, and submucosa. Chronic visceral hypersensitivity model induced by intracolonic TNBS.
Limitations
- Animal (mouse) model — translation to human nociception requires caution
- Ex vivo preparations may not fully replicate in vivo neuronal environment
- Acute experimental design; long-term nociceptor modulation not assessed
- Specific cGMP receptor on nociceptors not fully identified at time of publication
Clinical Relevance
This landmark mechanistic study explains the dual action of linaclotide: (1) secretory/pro-motility via intracellular cGMP and CFTR activation, and (2) analgesic via extracellular cGMP inhibition of nociceptors. This is particularly important because IBS-C patients report abdominal pain as their most bothersome symptom. The finding that linaclotide is more effective at inhibiting hypersensitized nociceptors suggests it is specifically suited for pathological pain states, not just normal physiology.
Related
#research #animal-in-vivo #in-vitro #evidence-level-V #gastrointestinal #linaclotide